A patient came back to my office last month with a folder of pharmacy receipts — three different triptans, then a gepant, none of it touching her migraines for more than a few hours. She asked me, half joking, half not: “Is there anything left?” There is. It’s one of the oldest migraine drugs we have, and in my experience it’s also one of the most underused: dihydroergotamine, or DHE.
What DHE actually is, and why it’s different
DHE is an ergot derivative, chemically related to the ergotamine used in migraine treatments for close to a century. Like triptans, it binds serotonin (5-HT1B/1D) receptors and constricts dilated cranial blood vessels. But it doesn’t stop there — DHE also acts on dopamine and adrenergic receptors, and it binds more tightly and for longer than any triptan. That broader, stickier receptor profile is exactly why it can work when a triptan or a gepant (Nurtec, Qulipta, Ubrelvy) hits a wall. If you’ve already been through that particular disappointment, I’ve written more about why triptans stop working and why gepants fail for some patients — DHE is usually the next branch in that decision tree, not the first.
The other thing that sets DHE apart is durability. Triptans have a habit of wearing off in four to six hours, letting the migraine roar back before the next dose is due — a pattern I covered in this piece on migraine recurrence. DHE’s longer half-life and slower receptor dissociation mean recurrence is much less common. For patients whose migraines are less about peak intensity and more about a headache that simply won’t quit for two or three days, that durability matters more than raw potency.
Who I actually offer it to
I reach for DHE in three situations. First, true triptan and gepant failure — someone who has honestly tried at least two triptans from different chemical subclasses (not just two brands of the same molecule) plus a gepant, at the right dose, early enough in the attack, and still gets no relief. Second, status migrainosus — an attack that has run past 72 hours without a real break, which I discuss in more depth in this article on prolonged migraine. IV DHE, often combined with an antiemetic, is one of the most reliable ways I know to break that kind of attack in an infusion or ER setting. Third, patients with frequent recurrence despite otherwise adequate triptan response — DHE’s staying power solves a problem the triptan itself never could.
DHE is not a casual, every-week option, and it’s not first-line. It’s a tool for attacks that have already beaten your first- and second-line medications. If your migraines are frequent enough that you’re reaching for any acute drug more than nine or ten days a month, the more urgent conversation isn’t which rescue medication to escalate to — it’s whether you’re sliding into medication overuse headache, which can make every acute treatment look like it’s failing when the real problem is the overuse pattern itself.
How it’s actually given
There are three practical forms. The nasal spray (Trudhesa, Migranal) is the one most patients can use at home — it’s far better absorbed than the old nasal formulation from the 1990s, though it still commonly causes nasal congestion or a strange taste. Self-injectable DHE, given subcutaneously or intramuscularly, works faster and is what I prescribe for patients who’ve failed nasal DHE or need something more reliable during a severe attack; it does require a bit of teaching before someone feels comfortable self-injecting. IV DHE, given in an infusion center or emergency department — often as a repeated-dose protocol over one to three days alongside an antiemetic like metoclopramide — is reserved for status migrainosus or attacks that have failed everything else at home.
Nausea is the most common limiting side effect, which is why we almost always pair DHE with an antiemetic, especially for the injectable and IV forms. Because of the vasoconstriction, DHE is contraindicated in uncontrolled hypertension, coronary artery disease, peripheral vascular disease, and pregnancy, and it can’t be combined with triptans within 24 hours or with certain other vasoconstrictors. It also needs caution alongside strong CYP3A4 inhibitors. None of this makes it a dangerous drug in the right patient — but it does mean the decision to prescribe it should come after a real look at your cardiovascular history, not just a quick refill request.
What I tell patients before they try it
DHE isn’t a magic reset button, and it doesn’t work for everyone who’s failed triptans — nothing does. But in patients who’ve genuinely exhausted the standard escalation ladder, I see meaningful relief often enough that I bring it up long before considering it a last resort. If you’ve been told your migraines are “treatment-resistant” but no one has specifically discussed DHE with you, that’s worth raising at your next visit. And if the honest answer is that you can’t remember the last day you didn’t take some kind of headache medication, that’s a different, more urgent conversation than which drug to try next — read more in why your headache isn’t getting better.
Not sure whether your headache pattern needs urgent evaluation? Start with our free, two-minute Headache Red Flags checklist. If you want a specialist to actually review your medication history and attack pattern, you can talk to a specialist here.
This article is for educational purposes and is not a substitute for medical care. It does not replace an in-person evaluation by a physician. If you’re experiencing a sudden, severe, or unusual headache, or any neurological symptoms, seek emergency care immediately.
From the textbook. Chapter 14, “Acute Treatment of Migraine,” of my clinical textbook Headache Medicine covers this topic in full for doctors, with the evidence and decision pathways behind it. About the book →